Basilea Pharmaceutica BSLN

SWX: BSLN | ISIN: CH0011432447   27/06/2025
47,60 CHF (-0,83%)
(-0,83%)   27/06/2025

5 juni 2025 · Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea · Persbericht

20 mei 2025 · Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States · Persbericht

24 april 2025 · Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea · Persbericht

16 april 2025 · Basilea shareholders approve all proposals of the board of directors at the annual general meeting · Persbericht

16 april 2025 · Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025 · Persbericht

14 maart 2025 · Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea · Persbericht

18 februari 2025 · Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow · Persbericht

5 februari 2025 · Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea · Persbericht

28 januari 2025 · Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea · Persbericht

8 januari 2025 · Basilea provides portfolio update and outlook · Persbericht

23 december 2024 · Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics · Persbericht

16 december 2024 · Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States · Persbericht

10 oktober 2024 · Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year · Persbericht

24 september 2024 · Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis · Persbericht

19 september 2024 · Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding · Persbericht

6 september 2024 · Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea · Persbericht

27 augustus 2024 · European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea · Persbericht

21 augustus 2024 · Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea · Persbericht

13 augustus 2024 · Basilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidance · Persbericht

20 juni 2024 · Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation · Persbericht

Mijn selecties